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 1 
Abstract: 1 
The aim of this study was to compare protein-loaded inhalable microparticles 2 
manufactured using a range of biocompatible polymers including hydroxypropyl cellulose 3 
(HPC), chitosan, hyaluronic acid, alginate, gelatin, ovalbumin and poly (lactide-co-4 
glycolide)(PLGA). Spray drying was used to prepare microparticles containing bovine 5 
serum albumin labeled with flourescein isothiocyanate (BSA-FITC). Particles of respirable 6 
size and high protein loading were obtained. No evidence of BSA degradation was seen 7 
from PAGE analysis. The microparticles were mixed with mannitol as a carrier and 8 
powder aerosolization was assessed with a multi-dose dry powder inhaler (DPI) using a 9 
multi-stage cascade impactor. The mass median aerodynamic diameter (MMAD) ranged 10 
between 2.9-4.7m. Potential polymer toxicity in the lungs was compared by impinging 11 
the particles on Calu-3 monolayers and assessing the cytotoxicity, induction of cytokine 12 
release, changes in transepithelial permeability and electrical resistance. No toxic effects 13 
were observed with most of the polymers though some evidence of compromised cell 14 
monolayer integrity was seen for PLGA and ovalbumin. PLGA and gelatin microparticles 15 
caused a significant increase in IL-8 release. Of the polymers studied, PLGA showed the 16 
greatest toxicity. Certain polymers showed particular promise for specific protein delivery 17 
needs in the lungs, such as HPC to improve flow properties, sodium hyaluronate for 18 
controlled release, and chitosan and ovalbumin for systemic delivery. 19 
Keywords: Pulmonary drug delivery; protein; microparticles; calu-3; toxicity.
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1. Introduction 1 
Inhalation therapy is a widely used and well accepted treatment for many lung 2 
diseases. As a portal for non-invasive drug delivery, the pulmonary route is attractive. The 3 
lungs possess many favorable characteristics including a large absorptive surface area 4 
(100 m2), extensive vasculature, thin alveolar epithelium (0.1-0.2 μm) and short distance of 5 
air-blood exchange passage (Patton et al., 1992). There has been particular interest in 6 
pulmonary delivery of macromolecules for both local and systemic delivery (Scheuch et al., 7 
2006). The most notable being inhaled insulin. Exubera, a dry powder form of insulin was 8 
approved in early 2006 but was recently removed from the market (Mack, 2007). Inhalation 9 
of proteins/peptides is not without its difficulties. These can include protein denaturation 10 
during manufacture, aerosolization and storage, poor powder flowability resulting in 11 
inefficient delivery, rapid clearance from the lungs due to mucociliary clearance, enzymatic 12 
degradation and  phagocytosis by alveolar macrophages (Boer et al., 2001).  13 
Several approaches have been used to overcome these problems. One of the most 14 
versatile strategies is the bioengineering of inhalable particles using biocompatible 15 
polymers. Such polymers have been used to improve protein stability and enhance their 16 
absorption via the lungs (Sakagami et al., 2001), improve particle aerodynamic properties 17 
(Sham et al., 2004), achieve controlled/sustained release (Huang et al., 2002) or escape 18 
the natural phagocytic clearance in the lungs (Edwards et al., 1997). Many of these 19 
formulations have yet to be commercialised and this delay can be attributed to many 20 
factors including: a lack of comparative data on polymer influence on the aerodynamic 21 
properties of dry powders for inhalation, the lack of licensed excipients and standardized 22 
biopharmaceutical testing methods for the pulmonary route, and concerns regarding the 1 
safety and clearance of these polymers from the lungs. 2 
This study sought to compare a range of polymers including proteins, polyesters or 3 
water-soluble derivatives of proteins and sugars. These included sodium alginate, chitosan, 4 
gelatin, hydroxy propyl cellulose, PLGA, ovalbumin and sodium hyaluronate. Some of these 5 
have been investigated as potential carriers for the treatment of diseases such as 6 
tuberculosis (Suarez et al., 2001; Bivas-Benita et al., 2004; Zahoor et al., 2005), diabetes 7 
(Surendrakumar et al., 2003), asthma (Sakagami et al., 2002) and osteoporosis (Morimoto 8 
et al., 2000). Mucoadhesive polymers such as chitosan, sodium hyaluronate and HPC have 9 
been found to increase pulmonary absorption by delaying mucociliary clearance (Sakagami 10 
et al., 2001). Gelatin, albumin and PLGA have been found suitable for the targeting and 11 
controlled delivery of candidates such as salmon calcitonin, tetrandine and insulin to the 12 
lungs (Zeng et al., 1995; Edwards et al., 1997; Morimoto et al., 2000). The utility of such 13 
polymers as carriers has therefore been demonstrated in principle. However, little 14 
comparative data on the aerodynamic properties or toxicity and immunogenic potential of 15 
these polymers is available to allow formulation scientists to assess their usefulness for 16 
particular applications, eg. local versus systemic delivery. 17 
Inhalable protein-loaded microparticles of the selected polymers were manufactured 18 
by spray drying (Okamoto et al., 2002). A comprehensive comparison of the physico-19 
chemical properties of the microparticles was conducted including – size, morphology, 20 
protein-loading and stability, protein release and aerodynamic characteristics.The 21 
immortalized human airway epithelial cell line, Calu-3 was used to compare the interaction 22 
of the polymeric microparticles with the airway epithelium (Grainger et al., 2006). When 23 
cultured at an air-liquid interface, they form mucus producing, well differentiated and 1 
polarized monolayers with tight junctions that generate significant transepithelial electrical 2 
resistance (Foster et al., 2000). A simple, yet reproducible system was developed to 3 
impinge the microparticles on to Calu-3 monolayers cultured on Transwell® inserts. Cellular 4 
response to particle insult was measured in terms of cell viability (Knebel et al., 2002), 5 
cytokine (eg. IL-8) release (Abe et al., 2000), transepithelial resistance (Blank et al., 2006) 6 
and paracellular permeability (Robledo et al., 1999). 7 
2. Materials and methods 8 
2.1 Materials 9 
Fraction V Bovine Serum Albumin (BSA), BSA-Fluorescein Isothiocyanate (BSA-10 
FITC), low viscosity alginic acid sodium salt from Macrocystis pyrifera, low molecular 11 
weight chitosan, Gelatin (Type B from bovine skin), and albumin, grade II from chicken egg 12 
white were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Low viscosity 13 
hydroxy propyl cellulose (HPC-L) was a gift from Nippon Soda Co. Ltd., Japan. Sodium 14 
Hyaluronate was sourced from Shandong Freda Biochem Co. Ltd.,China. PLGA RG 504H 15 
was supplied by Boehringer Ingelheim (Ingelheim, Germany). D-Mannitol (Mannidex®) was 16 
a gift from Cerestar, Belgium. All other solvents or chemicals were of HPLC or analytical 17 
grade. Calu-3 cells were obtained from American Type Culture Collection (Rockville, MD, 18 
USA). Cell culture media and supplements were purchased from Gibco BRL (Paisley, 19 
Scotland). Tissue culture plastics were from Sarstedt AG & Co. (Germany) and Transwell 20 
clear polyester inserts (12mm diameter, pore size 0.4m) from Corning Costar (Corning, 21 
NY). 22 
 23 
2.2 Spray-drying 1 
BSA-FITC was dissolved in deionized water at 0.01%w/v and mixed with aqueous 2 
solutions (1%w/v) of alginic acid sodium salt, gelatin, HPC-L, ovalbumin or sodium 3 
hyaluronate. Chitosan was dissolved in 0.1%v/v HPLC-grade acetic acid. A protein:polymer 4 
ratio of 1:100 was used in all cases. In the case of PLGA microspheres, the protein was 5 
dissolved in deionized water and emulsified in the organic phase consisting of PLGA 6 
dissolved in Dichloromethane. Tween 20, at a concentration of 0.1% w/v, was used as the 7 
surfactant. The emulsion and above solutions were spray dried through a 0.5mm nozzle 8 
using a Buchi® 190 spray dryer (Buchi, Flawil, Switzerland) with an inlet temperature 9 
between 45-140°C and a feed flow rate of 4-5 ml/min. The recovered particles were stored 10 
in a desiccator at 4°C until further use.  11 
2.3 Determination of size, density and water content  12 
The particle size of the microparticles was determined by laser diffraction (Malvern 13 
Mastersizer 2000, Malvern Instruments Ltd, Malvern, UK) following suspension of the 14 
microparticles in isopropyl alcohol/ethanol and bath sonication for one minute. Dry 15 
dispersion was employed for particles of HPC-L. Morphological assessment was performed 16 
using a Hitachi scanning electron microscope (Model S3500N) after mounting the 17 
preparations on studs and sputter–coating with gold (Polaron SC500 Gold Sputter Coater, 18 
Quotum technologies, Newhaven, UK). The density () of the microparticles was 19 
determined as the tapped density using a tap density tester (Copley Scientific, Nottingham, 20 
UK) (Fiegel et al., 2004). The equilibrium moisture content of the particles was assessed by 21 
using a Q-500 thermogravimetric analyzer (TGA) (TA Instruments, New Castle, DE) 22 
(Sethuraman et al., 2002). 23 
2.4 Determination of protein loading, stability and distribution 1 
  To determine the protein loading, microsphere samples equivalent to approximately 2 
100g of protein were dissolved in 10ml of deionized water and the protein content was 3 
analyzed by UV spectrophotometry, at 495nm using a spectrophotometer (Biochrom, UK). 4 
In the case of chitosan microparticles, samples were dissolved in 0.1% acetic acid, 5 
precipitated with 0.4M NaOH and then centrifuged to remove the polymer prior to analysis 6 
(Witschi et al., 1999). PLGA microspheres were disrupted using 2.5%SDS/0.2M NaOH. 7 
The resulting mixture was neutralised to pH 7 by stepwise addition of 1M HCl (Gupta et al., 8 
1997). To eliminate interference from the reagents used for protein extraction, the samples 9 
(from both chitosan and PLGA) were filtered and analysed for BSA content using reverse-10 
phase HPLC (Perkin Elmer, Model Series 200).The system was equipped with a Gemini 11 
C18 column (5m, 250 x 4.6mm, Phenomenex, UK) and a UV detector (Perkin Elmer, 12 
Model Series 200) using the following conditions: detection wavelength -220nm; mobile 13 
phase A: 0.1%v/v trifluoroacetic acid (TFA) in water, mobile phase B: 0.08%v/v TFA in 14 
acetonitrile; flow rate: 1ml/min (Kohn et al., 2007). All determinations were performed in 15 
triplicate.  16 
The structural integrity of the encapsulated protein was assessed using 17 
Polyacrylamide Gel Electrophoresis (PAGE)(Igartua et al., 1998). BSA extracted from the 18 
microparticles was compared with native BSA and low molecular weight reference markers 19 
(29-205 kDa) (Sigma). Confocal Laser Scanning Microscopy (CLSM) was carried out using 20 
an LSM 510 Axio plan 2 upright confocal microscope (Carl Zeiss, Germany) at original 21 
magnification x63 using immersion oil both on the objective and to wet the dry 22 
microparticles. A krypton argon laser provided excitation light at 488 nm. 23 
2.5 Determination of aerosolization efficiency 1 
An Anderson Cascade Impactor (Copley Ltd., Nottingham, UK) was used to 2 
determine the dispersibility and fine particle fraction (FPF) of each powder/carrier blend 3 
through a DPI according to the manufacturer’s instructions. D-Mannitol (Mannidex, 4 
Cerestar, Belgium) was used as the carrier. It was sieved to give particles in the range 60 5 
to 125 m. It was then mixed with the microparticles at a ratio of 24:1 (mannitol: 6 
microparticles). To achieve uniform distribution, the blend was passed three times through 7 
a #125m sieve and further mixed in a glass mortar. Blend content uniformity were 8 
investigated by analyzing 50.0 ± 0.5 mg samples (n = 5) of each blend, according to the 9 
method described in Appendix XII H, Test B, Uniformity of Content of the British 10 
Pharmacopoeia (2004). Content uniformity for all blends gave a relative standard deviation 11 
of less than 5%. Each plate of the impactor was coated with a solution of Tween 80 in 12 
acetone (5%w/v). Acetone was evaporated by placing the plates in an oven at 60°C for 5 13 
minutes. About 25mg of the blend was manually loaded into the DPI and aerosolized by 14 
drawing air at a flow rate of 60 lmin-1 for 4 seconds through the impactor. Ten such doses 15 
were discharged into the apparatus. The washings from each stage were assayed for the 16 
content of BSA-FITC using HPLC (as described previously). The emitted dose (ED) is the 17 
total protein mass exiting the inhaler. Uniformity of emitted dose was determined using 18 
Apparatus B (Dosage Unit Sampling Apparatus- DUSA)(USP, 2000). Values were deemed 19 
acceptable if they were within 75-125% of the label claim. The recovered dose (RD) was 20 
taken as the cumulative mass of protein recovered (inhaler + all stages of the impactor) 21 
after each experiment. The Fine particle dose (FPD) was calculated as the quantity of 22 
protein recovered from Stage 2 to the Filter. The fine particle fraction (FPF) is the FPD 23 
expressed as a percentage of ED. The experimental mass median aerodynamic diameter 1 
(MMAD) and the geometric standard deviation (GSD) of the particles were also calculated 2 
(USP, 2000). All experiments were carried out in triplicate.  3 
2.6 In vitro protein release 4 
A Franz diffusion Cell fitted with a 0.45 μm pore cellulose acetate membrane filter 5 
was used to monitor in vitro protein release (Leitner et al., 2004). The receptor 6 
compartment contained pH 7.4 Phosphate buffer maintained at 37°C± 1°C. Microparticles 7 
(10mg) were deposited on the membrane at the air-liquid interface established by the 8 
filter. At selected times, 250 μl of the buffer was sampled from the receptor compartment 9 
and the volume replaced. The quantity of BSA-FITC released was determined using UV 10 
spectrophotometry as mentioned before. The in vitro drug release data were fitted in the 11 
Korsmeyer-Peppas (KP) equation, Mt/M∞=Ktn, where Mt & M∞ corresponds to the amount of 12 
drug released at time t and ∞ respectively, k is the kinetic constant, t is the release time 13 
and n is the diffusional component for drug release. 14 
2.7 Cell culture 15 
Calu-3 cells, an adenocarcinoma cell line derived from a 25 year old Caucasian 16 
male were purchased from the American Type Culture Collection (Rockville, Md., USA) at 17 
passage 14 and used between passages 20 and 50 (Grainger et al., 2006).  18 
2.8 Cell viability 19 
Calu-3 cells were plated at a density of 3 x 104/well in a 96-well format at 37°C in 5% 20 
CO2. After 24 hours of culture, a suspension containing 2mg of empty (unloaded) 21 
microparticles per ml of growth media was added to each well and incubated for either 4 or 22 
6 hours at 37°C and 5% CO2.  Cellular viability was assessed using the MTT (3-(4,5-23 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay (Gupta et al., 1 
2004). 2 
2.9 Microparticle application on calu-3 monolayers 3 
Calu-3 cells were seeded on to Transwell clear polyester inserts at a seeding density 4 
of 0.5 x 106 cells/cm2. They were grown at 37°C in a 90% humidified incubator with 5% 5 
CO2. For cells cultured under LLI (liquid-liquid interphase) conditions, 500l of media was 6 
added to the apical chamber and 1500l to the basolateral chamber. For cells cultured at 7 
an ALI (air–liquid interface) condition, the apical culture medium was removed 1 day after 8 
seeding and the basolateral medium was reduced to 650l. For both culture conditions, the 9 
media was replaced once daily. Blank microparticles were impinged on the monolayers on 10 
the 12th day after seeding. In the case of LLI monolayers, the apical media was aspirated 11 
and the basolateral volume was reduced to 650l before impingement. ALI grown 12 
monolayers were used as such. For the application of microparticles, the multi-well plate 13 
with the monolayers was placed in an airtight container as shown in Fig. 1. 1mg of the 14 
microparticles was weighed into the DPI. The vacuum pump was adjusted to deliver a 15 
constant suction. Filter inserts containing the monolayers were each placed in the first well 16 
under the tube. Microparticles were aerosolized onto the monolayers for 3 seconds. The 17 
inserts were then returned to their respective wells. 18 
To obtain data on the reproducibility of particle deposition, pre-weighed Transwell® inserts 19 
containing no cells (n=5) were slightly wetted with water and treated as described above for 20 
each polymer. After impingement, the inserts were left to dry and reweighed to determine 21 
the quantity deposited. 22 
 23 
2.9.1 Fluorescein-sodium transport across Monolayers 1 
After particles were aerosolized onto the cell monolayers, the filter inserts were 2 
placed into new wells containing 1500l of bicarbonated Krebs-Ringer (KRB) solution in the 3 
basolateral compartment. 500l of a 50M sodium fluorescein (flu-Na) solution in KRB was 4 
added to the apical compartment of each well. 100l samples were taken at predetermined 5 
intervals up to 4hours from the basolateral compartment and replaced with an equal 6 
amount of fresh buffer. The fluorescence of flu-Na was measured in 96 well plates using a 7 
fluorescence plate reader (Wallac Victor, Perkin Elmer, Cambridge, United Kingdom) at 8 
excitation and emission wavelengths of 488 and 530nm respectively. The apparent 9 
permeability coefficient values were calculated using the following equation: 10 
Papp = (1/ ACo) dQ/dt 11 
where Q, cumulative amount of Na-flu permeated across the cell monolayers over time t; A, 12 
surface area of transwells (1.12 cm2); C0, initial Na-flu concentration in the apical chamber. 13 
 14 
2.9.2 Bioelectric measurements 15 
Trans-epithelial electrical resistance (TEER) was measured with an EVOM® 16 
Epithelial Voltohmmeter device equipped with “chopstick electrodes” (World Precision 17 
Instruments, Sarasota, FL. USA). Monolayers grown under LLI conditions were used 18 
directly. Monolayers grown under ALI conditions had 750 l and 1500 l of prewarmed 19 
media added to the apical and basolateral sides, respectively, and were allowed to 20 
equilibrate for 10min in an incubator before the TEER was measured. TEER was 21 
expressed as cm2 after subtracting from the reading the resistance of the supporting filter 22 
and multiplying it by the surface area of the monolayer. 23 
 24 
2.9.3 Cytokine Release  1 
Basolateral media collected after 4 hours exposure to the microparticles were 2 
analyzed for IL-8 levels using ELISA MAXTM Kit (Biolegend, Inc.,San Diego, CA, USA). The 3 
assay detection limit was 30pg/ml. Collected media was diluted with the sample diluent and 4 
analyzed following protocols mentioned in the kit. 5 
2.10 Statistical Analysis 6 
Results are expressed as mean ±SD. One way ANOVA was used to test for 7 
differences between treatments. In cases where the differences in the mean values were 8 
significant, post hoc pair wise comparisons were done using Neumann-Keuls multiple 9 
comparison tests. A p value < 0.05 was taken as significant. 10 
3.0 Results 11 
3.1 Size, density and water content 12 
The particle size of the microspheres obtained after spray drying was dependent on 13 
the concentration (polymer and protein) of the spray solution and the spray flow rate 14 
(amount of compressed air needed to spray the solution). These parameters were 15 
optimised to obtain particles in the respirable size range. Table 1 gives the density and 16 
geometric diameter in m of the microparticles. The density was least in the case of HPC-L 17 
microspheres (0.09 ±0.02g/cm3) and highest in the case of chitosan microspheres 18 
(0.28±0.02g/cm3). 19 
The theoretical aerodynamic diameter of individual particles, daer, is related to the 20 
geometric diameter d (assuming particle sphericity) by the following expression:  21 
daer =  d x   22 
where  is the particle density and is 1gm/cm3(Hinds, 1999).The daer was 1 
calculated for each (Table 1) and found to be in the range 1-3 m.  2 
The Scanning Electron micrographs (Figure 2) show that the particles were smooth 3 
and spherical in the case of PLGA and alginate. Chitosan and sodium hyaluronate particles 4 
were spheroidal and corrugated. Ovalbumin and gelatin particles were toroidal and smooth. 5 
Particles made of HPC were crumpled. The water content (WC) from TGA analysis was 6 
least in the case of PLGA particles (0.49±0.01%w/w) and highest in the case of ovalbumin 7 
particles (10.47±0.76%w/w) (Table 1).  8 
3.2 Protein loading, stability and distribution 9 
The protein loading was determined as outlined in section 2.4 and compared with 10 
the theoretical loading to calculate protein encapsulation efficiency (%EE). %EE was 11 
highest in the case of Alginate microspheres (96.9±0.55%) and least in the case of 12 
microspheres manufactured from Chitosan (59.2±0.78%). %EE for the other polymers was 13 
62.6±1.2% (PLGA), 95.8±1.2% (gelatin), 88.9±1.3% (HPC), 96.7±1.4% (ovalbumin), and 14 
89.2± 1.2% (sodium hyaluronate). The effect of spray drying on the structural integrity of 15 
BSA was investigated using SDS-PAGE. No degraded protein fragments or covalent 16 
aggregates could be detected in all the formulations tested (data not shown).  17 
CLSM can be used as a non-destructive visualization technique for microparticles 18 
containing a fluorescently labeled protein (Lamprecht et al., 2000). A homogeneous 19 
distribution of BSA-FITC can be seen within the loaded polymeric particles except in the 20 
case of gelatin and PLGA (Fig. 3). In the batches of PLGA and chitosan, empty 21 
microspheres were seen which may explain their relatively low %EE compared to the other 22 
polymers.  23 
3.3 Aerosolization efficiency 1 
Microparticles blended with mannitol were aerosolised at 60 l/min through a DPI 2 
using an Andersen cascade impactor. The deposition data (Table 2) was calculated taking 3 
into account the assay values of the microparticles. The recovered dose (RD) ranged 4 
between 83-95% of the loaded dose. The Fine particle fraction (FPF) was highest in the 5 
case of HPC-L particles (26.1%) and lowest with Ovalbumin particles (11.9%). The other 6 
polymers produced FPF values between 14-21%. The MMAD values were larger than the 7 
theoretical daer (calculated in section 3.1) and ranged between 2.9-4.7m possibly due to 8 
particle aggregation. Emitted dose uniformity for all formulations as tested using DUSA 9 
were in the acceptable range (80.9-91%). The values were 82.4±7.5% (chitosan), 10 
84.4±6.1% (alginate), 85.5±8.7% (PLGA), 80.9±2.3% (gelatin), 91.1±4.5% (HPC), 11 
81.3±3.2% (ovalbumin), and 80.2±2.6% (sodium hyaluronate). 12 
3.4 In-vitro protein release 13 
  To determine the effect of polymers on protein release rates, studies were carried out 14 
as described in section 2.6. Figure 4 shows the cumulative BSA-FITC release profiles from 15 
the microparticles. At the end of 3 hours, near complete release was seen with particles 16 
made of HPC and gelatin. Release from PLGA particles was negligible (0.2%). For all 17 
other polymers, the release ranged between 17-43% after 3 hours. Application of the 18 
Peppas model to determine release kinetics resulted in coefficient of determination (R2) 19 
values between 0.93-0.99 for all polymers except PLGA. The diffusion component (n) 20 
ranged between 0.39-0.43 for alginate, chitosan, gelatin, ovalbumin and sodium 21 
hyaluronate. The value of n was 0.65 for HPC. 22 
 23 
3.4 Polymer toxicity 1 
3.4.1 MTT assay 2 
  For the MTT assay, a particle dose of 2mg/ml was used based on the theoretical 3 
concentration of dry powder that would deposit in the central and intermediate lung after 4 
inhalation of a standard 40mg dose (Newman et al., 2002; Widdicombe, 2002; Newhouse 5 
et al., 2003). Table 3 shows that after 4 or 6 hours exposure to the microparticles, no 6 
significant difference (p>0.05) in viability was observed between the cells treated with 7 
microparticles and the untreated control cells. 8 
3.4.2 Bioelectric measurements 9 
TEER measurements were used in order to assess the effect of the polymers on the 10 
tight junctional integrity of Calu-3 cell monolayers. From deposition reproducibility studies 11 
with blank filters, it was found that 576±128 g of microparticles was delivered on each 12 
insert (area of insert: 1.1cm2) using the apparatus shown in Figure 1.  The exposure dose 13 
used is approximately 250 times greater than what would be expected based on the 14 
ICRP66 model (ICRP, 1994). Prior to particle impingement, cells grown under LLI 15 
conditions exhibited a mean TEER value of 1870±48 cm2 and those grown under ALI 16 
conditions exhibited a mean value of 774±16 cm2. On removal of apical media from the 17 
LLI monolayers for particle impingement, a sharp drop in electrical resistance was 18 
observed which did not recover during the course of the study. Four hours post treatment, a 19 
further drop in TEER was observed for monolayers treated with chitosan, gelatin, sodium 20 
hyaluronate and ovalbumin. Three days later, the TEER values for the treated cells had 21 
recovered to values between 450-650cm2 for all polymers except PLGA and ovalbumin. A 22 
TEER value  450cm2 is indicative of a tight calu-3 monolayer (Sanjar et al., 2001). In 23 
contrast, monolayers grown under ALI conditions showed no significant drop in TEER value 1 
after treatment except in the case of PLGA and ovalbumin microparticles (Figure 5). After 3 2 
days however, TEER values returned to initial levels for all treated cells except those 3 
impinged with PLGA. 4 
3.4.3 Transport study with Sodium Fluorescein 5 
The transport of a paracellular marker, sodium fluorescein across Calu-3 cell 6 
monolayers, cultured under ALI and LLI conditions, was studied in the presence of 7 
impinged microparticles. Flux and Papp were calculated from a plot of the cumulative 8 
amount of Na-Flu transported as a function of time. Only PLGA and ovalbumin caused a 9 
significant increase in Na-Flu transport (p<0.05) (Table 3). An increase in Na-Flu transport 10 
was also seen with chitosan for cells cultured under ALI conditions, although this was not 11 
significant. 12 
3.4.4 Cytokine production 13 
 Upon stimulation by immunogenic airborne particulates, airway epithelial cells 14 
release cytokines such as Interleukin-8 (IL-8) which attracts and activates inflammatory 15 
cells in the airways and contributes to the pathogenesis of airway disorders. After 4 hours 16 
of apical exposure to the polymeric microparticles, polarized calu-3 cells secreted IL-8 at 17 
levels from 240-2100pg/ml consistent with previous studies (Witschi et al., 1999). As shown 18 
in Table 3, IL-8 production was significantly increased (p<0.05) from the control (air 19 
impinged) monolayers in the case of gelatin and PLGA.  20 
4. Discussion 21 
Spray drying produced microspheres with a protein encapsulation efficiency 22 
between 59-97%. The microspheres had a calculated aerodynamic diameter (daer) in the 23 
range 1-3 m and particles with a daer between 0.02-0.05m and 2-5m are capable of 1 
alveolar deposition (Hanes et al., 2003).  2 
A homogenous protein distribution within all the polymeric particles except gelatin 3 
and PLGA (as seen by CLSM) is expected since the feed to the spray dryer is a neat 4 
solution of the protein and polymer dissolved in purified water. The punctate and non-5 
uniform distribution of BSA within the gelatin microspheres produced from a neat solution 6 
could indicate a protein-protein interaction. In the case of PLGA particles where a w/o 7 
emulsion was used, BSA could be expected to accumulate at the water-solvent interface 8 
because of its surfactant properties. The fluorescent corona seen in this case is similar to 9 
those previously reported (Lamprecht et al., 2000).  10 
When aerosolized alone, the forces generated within the DPI were insufficient to 11 
entrain the microparticles as a result of poor flow and particle aggregation. Entrainment 12 
was aided by the addition of a coarse carrier, mannitol (Chan et al., 1997).  In addition to 13 
powder entrainment, one of the key factors that determines FPF is the ability of the inhaler 14 
to generate forces sufficient to deagglomerate the microparticles from the carrier. The FPF 15 
values for the polymeric microparticles in the present study were 12-26%. The degree to 16 
which the microparticles are released from mannitol during aerosolisation is influenced by 17 
factors such as the size of the microparticles, their shape, surface roughness and moisture 18 
content. In the case of irregularly shaped particles or those with a rough surface, the area 19 
of contact is reduced. These particles are thought to experience reduced adhesive forces 20 
(Maugis, 1996). The SEMs indicated a polymer dependent difference in the shape and 21 
surface properties of the microparticles manufactured in this study. The collapsed, raisin- 22 
like shape of HPC particles coupled with a low residual moisture content could have 23 
facilitated deagglomeration resulting in a relatively high FPF (Table 2). The low FPF seen 1 
with ovalbumin particles could be due to particle aggregation as a result of high residual 2 
moisture. Incomplete powder deaggregation in the DPI could have also resulted in the 3 
experimental MMADs of the microparticles being 2-3 times larger than the theoretical 4 
aerodynamic diameter, daer (Bosquillon et al., 2001) as calculated in Table 1. 5 
The amount of liquid available for the dissolution of a therapeutic aerosol in the 6 
lungs is very small (Patton, 1996). For protein release studies, open membrane systems 7 
have been employed previously as a representative technique (Witschi et al., 1999). A 8 
novel approach using Franz diffusion cells was used in this study (Franz, 1975). These 9 
cells are not suited for prolonged drug release studies because of evaporation of release 10 
media from the lower compartment. This is a limitation of the device. No pharmacopoieal 11 
methods are presently available to understand drug release from a formulation following its 12 
deposition in the lungs. The diffusion coefficient (n) values with the KP equation were less 13 
than 0.43 for alginate, chitosan, gelatin, ovalbumin and sodium hyaluronate particles 14 
indicating protein release by Fickian diffusion through water-filled pores in the polymer 15 
network (Peppas, 1985). Matrix swelling/erosion effects were not evident possibly due to 16 
the small volume of release media that seeps into the upper chamber. Polymer relaxation 17 
effects were seen however with HPC particles. The n value in this case was 0.65 indicating 18 
anomalous (non-Fickian) release kinetics. Drug release rates in the case of Fickian 19 
diffusion is governed by factors such as polymer hydrophilicity, pore size of the polymer 20 
network and overall net charge carried by the protein/polymer. One or more of the above 21 
factors could have contributed to the differences in protein release rate observed between 22 
the polymers. The rapid release observed with gelatin could be due to the uncoiling of its 23 
triple helical structure when exposed to body temperatures. In the case of HPC, both 1 
diffusion and polymer erosion combined to give a high release rate. Sodium Hyaluronate 2 
displayed the lowest release rate (excluding PLGA). This could indicate that it underwent 3 
hydration more rapidly than the other polymers. Hydration produces a gelatinous mass, the 4 
thickness of which then determines the diffusional path length for the protein. The longer 5 
the path length, the slower would be the rate of release (Sujja-areevath et al., 1998; 6 
Surendrakumar et al., 2003). Negligible protein release from PLGA particles could be 7 
attributed to its strongly hydrophobic nature resulting in poor wetting. Indeed the t1/2 for 8 
hydrolysis of PLGA in the lungs is expected to be in the order of several months (Dunne et 9 
al., 2000). Chitosan and sodium hyaluronate appear best suited for sustained release of 10 
proteins/peptides in the lungs. Their mucoadhesive properties could also be exploited to 11 
reduce particle clearance by ciliary movement. Another important factor in sustained 12 
release to the lungs using microparticles is alveolar macrophage avoidance. Some 13 
strategies to reduce particle phagocytosis include coating with phospholipids, precoating 14 
with BSA and nonproteinaceous macromolecules (Cryan, 2005), and control of the particle 15 
size and density (Edwards et al., 1997). 16 
The polymers considered in the present study have all received the G.R.A.S 17 
(Generally Regarded As Safe) status from the US FDA. However the toxicity of a 18 
substance varies greatly with the route of administration and excipients considered safe for 19 
ingestion may not be safe for inhalation. Upon inhalation and release of the drug payload, 20 
the polymers and their degradation products must be non-toxic and non-immunogenic. It is 21 
believed that exposure of lung epithelial cells to foreign particulate matter can cause 22 
disruption of the epithelial tight junctions and formation of intercellular channels for the 23 
passage of molecules from airway lumen to blood. The MTT assay indicated no major 1 
cytotoxicity up to 6 hours after exposure of the cells with the polymeric microparticles. 2 
Exposure of submerged cell monolayers to suspended particles is a traditional approach to 3 
study particle-cell interactions and their effect on monolayer integrity. To better mimic the in 4 
vivo situation of an air-liquid interface, a novel method was devised in this study to impinge 5 
dry microparticles directly on to calu-3 cells grown on porous supports.  6 
Inspite of the extremely high particle exposure dose, after 72 hours cytotoxicity was 7 
observed only with ovalbumin and PLGA (under LCC conditions) and only with PLGA 8 
(under ALI conditions). Consistent with the TEER observations, Papp values for sodium 9 
fluorescein were highest in the case of PLGA and ovalbumin (Table 3). Alteration of the 10 
barrier function could occur by a number of mechanisms including tyrosine phosphorylation 11 
or dislocation of  junctional proteins (Atkinson et al., 2001) or interaction of cationic species 12 
with the negatively charged glycocalyx of cell membranes (Yu et al., 1994).  13 
A decrease in epithelial integrity on treatment with ovalbumin has previously been 14 
reported (Evans et al., 2002). In this study, treatment of ALI cultured Calu-3 cells caused 15 
only a transient disruption of the barrier properties and TEER recovered to pre-16 
impingement values after 24 hours. The increase in Papp for sodium fluorescein in the 17 
presence of chitosan (though not significant) for cells under ALI culture is consistent with 18 
previous studies showing the epithelial permeability enhancing effects of chitosan (Smith et 19 
al., 2004). The transient opening of epithelial tight junctions in the case of ovalbumin and 20 
chitosan could be exploited for absorption enhancement in systemic protein delivery via the 21 
lungs. 22 
Production of the inflammatory cytokine, IL-8 was significantly increased (p<0.05) in 1 
the case of PLGA and gelatin microparticles which is indicative of their immunogenicity. 2 
The highest secretion (1964±219 pg/ml) was observed in the case of gelatin. This could be 3 
due to endotoxin contamination in the raw material used (Witschi et al., 1999). 4 
5. Conclusion 5 
While the concept of controlled and targeted delivery is well established for oral and 6 
parenteral use, its application for pulmonary drug delivery is a new area lacking 7 
fundamental data. Commercial formulations based on these technologies have yet to make 8 
it to market and this can be attributed in some part to the lack of comparable data of 9 
potential excipients, concerns regarding the safety and clearance of these polymeric 10 
carriers from the lungs and the dearth of standardised biopharmaceutical testing methods 11 
for the pulmonary route. In this paper, a comprehensive comparison of a range of protein-12 
loaded polymeric particles for inhalation was conducted. The effects of the polymers on the 13 
delivery and release of proteins in the lungs and their biocompatibility was modelled using 14 
innovative methods. From our studies certain polymers would appear suited to meet 15 
different respiratory delivery needs eg. high delivery efficiency (HPC), low toxicity and 16 
controlled release (sodium hyaluronate and chitosan), and improved systemic delivery 17 
(ovalbumin and chitosan). Interestingly, one of the most commonly studied excipients for 18 
controlled release in the lungs, PLGA, had the greatest toxicity of the polymers studied. 19 
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Tables: 
 
Table 1: Size, density and water content of polymeric microparticles (mean±SD, n=3) 
Polymer 
Geometric 
diameter 
(d)(m) 
density() 
(g/cm3)  
dae(m)
 
Water 
content 
(%) 
Chitosan 5.49±0.32 0.28±0.02 2.91 5.03±0.17 
Alginate 3.23±0.25 0.22±0.02 1.52 6.73±0.09 
PLGA 5.5±0.41 0.11±0.02 1.82 0.49±0.01 
Gelatin 2.88±0.2 0.18±0.02 1.22 4.84±0.07 
HPC-L 4.61±0.16 0.09±0.04 1.38 1.8±0.08 
Ovalbumin 4.29±0.38 0.11±0.05 1.42 10.47±0.76 
Sodium 
Hyaluronate 
3.61±0.35 0.12±0.02 1.25 
3.22±0.05 
 
Table 2: Deposition in an anderson cascade impactor after aerosolisation of 
mannitol blended microparticles from a DPI at 60 l/min (mean±SD, n=3) 
Polymer FPF(%)a MMADb GSDc 
Chitosan 15.4±5.1 3.9±0.2 2.06±0.1 
Alginate 20.7±6.1 4.1±0.3 1.88±0.07 
PLGA 13.9±4.3 2.9±0.2 2.05±0.1 
Gelatin 18.9±4.8 4.7±0.4 1.92±0.12 
HPC-L 26.1±3.9 3.3±0.6 1.91±0.05 
Ovalbumin 11.9±4.3 4.2±0.3 1.85±0.1 
Sodium Hyaluronate 19.9±7.2 4.6±0.2 1.89±0.2 
aFPF is the Fine Particle Fraction 
bMMAD is the Mass Median Aerodynamic Diameter 
cGSD is the Geometric Standard Deviation 
Table 3: Toxicity and immunogenicity of microparticles in Calu-3 cells: Papp of 
Fluorescein Sodium, cell viability and cytokine release  
Treatment 
Papp (x 10-7cm/sec)  
of Fluorescein Sodium % cell viability
* IL-8 
(pg/ml)* 
 
ALI LLI 
Exposure  
4 hours 6hours 
Air impinged 1.19±0.12 0.85±0.02 NA NA 274±33 
HPC-L 1.38±0.22 1.28±0.27 101±3 89±5 382±64 
Alginate 1.61±0.23 1.71±0.28 91±18 82±12 352±87 
Chitosan 2.29±0.02 1.28±0.17 97±2 95±2 467±108 
Gelatin 1.61±0.19 1.71±0.09 83±12 94±15 1964±219‡ 
Sodium Hyaluronate 1.66±0.74 0.93±0.13 85±4 78±7 417±83 
Ovalbumin 11.9±2.89‡ 20.72±1.88‡ 129±23 113±2 468±51 
PLGA 9.52±3.29‡ 6.91±1.15‡ 98±2 97±1 538±108‡ 
* Mean±SD (n=4), ‡ Significantly different compared to control (p<0.05) 
 
 
 
 
 
 
Figure Legends: 
Figure 1: Apparatus used for particle impingement on cell monolayers. 
 
Figure 2: Scanning electron micrographs of BSA loaded microparticles: Alginate 
(A); Chitosan (B); PLGA (C); Gelatin (D); Sodium Hyaluronate (E); Ovalbumin 
(F); HPC (G) 
 
Figure 3: Confocal Laser Scanning Microscopy images of microparticles 
containing BSA-FITC (green), Differential Interference contrast image(grey); A,B: 
Alginate; C,D: Chitosan; E,F: PLGA; G,H: Gelatin 
 
Figure 4: Protein release profiles from spray-dried microparticles carried out 
using Franz diffusion cell (Mean ± SD, n=3) 
 
Figure 5: Time course of change in TEER values in calu-3 cell monolayers after 
exposure to polymeric microparticles under ALI conditions (Mean ± SD, n=4) 
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